TCOV
AXDX

Trust Company of Vermont’s Accelerate Diagnostics AXDX Stock Holding History

Trust Company of Vermont’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-50
Closed -$10K – 859
2016
Q4 		$10K Hold
50
– – ﹤0.01% 701
2016
Q3 		$14K Sell
50
-50
-50% -$11.1K ﹤0.01% 615
2016
Q2 		$14K Buy
+100
New +$13.4K ﹤0.01% 570

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return

Trust Company of Vermont's AXDX Position: Q1 2017 in Review

Trust Company of Vermont sold out of Accelerate Diagnostics (AXDX) in Q1 2017, closing a stake of 50 shares — an estimated $10K sold.

Trust Company of Vermont first reported a position in AXDX in Q2 2016 and held it in 3 quarters. The position peaked at $14K in Q3 2016. 98 funds tracked by Wall St. Rank hold AXDX as of Q1 2017.

  • Trust Company of Vermont reported no remaining Accelerate Diagnostics position as of Q1 2017 after selling out during the quarter.
  • Trust Company of Vermont sold 50 Accelerate Diagnostics shares in Q1 2017, an estimated $10K.
  • Trust Company of Vermont first reported a position in Accelerate Diagnostics in Q2 2016 and held it in 3 quarters.
  • Trust Company of Vermont's Accelerate Diagnostics position peaked at $14K in Q3 2016.
  • 98 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2017.

Based on Trust Company of Vermont's 13F filing for Q1 2017, filed 4 May 2017.